Qiagen N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights globally. The company offers sample technology consumables, including nucleic acid stabilization and purification kits for sample materials, as well as silica membranes and magnetic bead technologies. Its portfolio includes secondary sample technology consumables like kits and components for nucleic acid purification, and instruments for nucleic acid purification and quality control. Qiagen also provides immune response consumables such as interferon-gamma release assays for TB testing and assays for post-transplant testing and viral load monitoring. Additionally, it offers oncology and sexual and reproductive health consumables, including assays for prenatal testing, detection of sexually transmitted diseases and HPV, and analysis of genomic variants. The company serves research and clinical diagnostics markets.

Qiagen N.V. is listed on the New York Stock Exchange (NYSE) under the ticker symbol QGEN. The company trades in US Dollars (USD). As a Netherlands-based company with a US listing, it provides investors access to its stock in the US market. The choice of NYSE and USD trading facilitates investment from a broad international investor base, particularly those in the United States. The company's primary listing on a major US exchange ensures liquidity and visibility among global investors.

Qiagen N.V. operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry focuses on developing tools and technologies for diagnosing diseases, monitoring health conditions, and conducting biomedical research. As a diagnostics and research company, Qiagen provides products that enable molecular insights from biological samples, supporting applications in areas such as oncology, infectious disease testing, and genetic analysis. The company's offerings are used by hospitals, laboratories, and research institutions worldwide.

Qiagen N.V. is headquartered in the Netherlands, as indicated by its country of incorporation. The company operates globally, providing its sample to insight solutions to customers worldwide. Its products are used in various markets including clinical diagnostics, academic research, pharmaceutical development, and applied testing. Qiagen's global presence allows it to serve customers in regions such as North America, Europe, Asia, and other parts of the world. The company's solutions are designed to meet the needs of both developed and emerging markets, supporting a wide range of molecular biology applications.

Qiagen N.V.'s portfolio includes several main product categories. Sample technology consumables encompass nucleic acid stabilization and purification kits, as well as silica membranes and magnetic bead technologies. Secondary sample technology consumables include kits and components for nucleic acid purification, along with instruments for purification and quality control. Immune response consumables feature interferon-gamma release assays for TB testing and assays for post-transplant testing and viral load monitoring. Oncology and sexual and reproductive health consumables include assays for prenatal testing, detection of sexually transmitted diseases and HPV, and genomic variant analysis. Additionally, the company offers research PCR consumables such as quantitative PCR and reverse transcription kits, as well as PCR instruments including digital PCR and qPCR solutions. Human ID/forensics assay consumables comprise short tandem repeat assays for human identification and food contamination assays.